Metraipolis › archive › dc_a0da2e5e26aa

Durability of the BNT162b2 XBB:1.5-adapted vaccine against JN.1 hospitalisation in Europe, October 2023 to August 2024: A test-negative case-control study… — Europe PMC PMID:41671248

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41671248
DOI
10.1371/journal.pone.0342382
License (as archived)
solo-consultazione
Archived
2026-11-05T22:50:26.038Z
SHA-256 of the archived text
048d1568cc2e9d0176f9bdef07900aa326eac5b003658ca6208c0d85d1e289c3
Stable URL of this page
https://metraipolis.com/documento/dc_a0da2e5e26aa

How to cite

Durability of the BNT162b2 XBB:1.5-adapted vaccine against JN.1 hospitalisation in Europe, October 2023 to August 2024: A test-negative case-control study… — Europe PMC PMID:41671248 — Europe PMC (en), https://europepmc.org/article/MED/41671248 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a0da2e5e26aa (Metraipolis archive dc_a0da2e5e26aa, sha256 048d1568cc2e9d0176f9bdef07900aa326eac5b003658ca6208c0d85d1e289c3)
BibTeX
@misc{dca0da2e5e26aa,
  title = {Durability of the BNT162b2 XBB:1.5-adapted vaccine against JN.1 hospitalisation in Europe, October 2023 to August 2024: A test-negative case-control study… — Europe PMC PMID:41671248},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41671248},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a0da2e5e26aa; sha256 048d1568cc2e9d0176f9bdef07900aa326eac5b003658ca6208c0d85d1e289c3},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41671248. Agents can read the archived copy with the MCP tool read_document.